Dated: May 9, 2013.

#### Melanie J. Grav,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2013-11494 Filed 5-14-13; 8:45 am]

BILLING CODE 4140-01-P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### **National Institutes of Health**

# National Institute of General Medical Sciences; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of General Medical Sciences; Initial Review Group, Training and Workforce Development Subcommittee—A.

Date: June 19, 2013.

Time: 8:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Courtyard by Marriott, 5520 Wisconsin Avenue, Chevy Chase, MD 20815. Contact Person: John J. Laffan, Ph.D., Scientific Review Officer, Office of Scientific Review, National Institute of General Medical Sciences, National Institutes of Health, 45 Center Drive, Room 3An.18J, Bethesda, MD 20892–4874, 301–594–2773,

laffanjo@mail.nih.gov.

Name of Committee: National Institute of General Medical Sciences Special Emphasis Panel COBRE.

Date: June 20–21, 2013.

Time: 8:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: DoubleTree by Hilton Bethesda, 8120 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Lisa A. Newman, SCD, Scientific Review Officer, Office of Scientific Review, National Institute of General Medical Sciences, National Institutes of Health, 45 Center Drive, Room 3As.19K, Bethesda, MD 20892–4874, 301–594–2704, newmanla2@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.375, Minority Biomedical Research Support; 93.821, Cell Biology and Biophysics Research; 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.862, Genetics and Developmental Biology Research; 93.88, Minority Access to Research Careers; 93.96, Special Minority Initiatives, National Institutes of Health, HHS)

Dated: May 9, 2013.

## Melanie J. Gray,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2013-11493 Filed 5-14-13; 8:45 am]

BILLING CODE 4140-01-P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

### **National Institutes of Health**

National Center for Advancing Translational Sciences; Request for Comment on Proposed Methods for Avoiding Duplication, Redundancy and Competition With Industry Activities

SUMMARY: The National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) invites comments regarding proposed methods it will use to avoid duplication, redundancy and competition with industry activities.

DATES: Comments regarding the proposed methods are due within 30 days of the date of this publication in the Federal Register.

**ADDRESSES:** Comments regarding the proposed methods should be sent to *comment@ncats.nih.gov*.

SUPPLEMENTARY INFORMATION: The Public Health Service Act indicates that the purpose of the National Center for Advancing Translational Sciences (NCATS) is to advance translational sciences by coordinating and developing resources that leverage basic research in support of translational science; and by developing partnerships and working cooperatively to foster synergy in ways that do not create duplication, redundancy and competition with industry activities.

Proposed Methods: In order to avoid duplication, redundancy and competition with industry activities, NCATS proposes to use one or more of the following methods that will allow the public, including industry, to be aware of its current activities and to have the opportunity to provide input: (1) Frequent updates to the NCATS Web site (www.ncats.nih.gov), which includes the NCATS Director's message and/or blog, listings of ongoing programs and projects, and notifications of solicitations for funding proposals for which industry may be eligible; (2) open public meetings to gather input on NCATS plans, priorities, and programs to which industry representatives are specifically invited; (3) discussion and

gathering input on NCATS plans, priorities, and programs of NCATS activities and concept clearances at the regular meetings of the NCATS Advisory Council and Cures Acceleration Network Review Board, which include members of the biotechnology, pharmaceutical, and venture capital communities; (4) meetings to gather input on NCATS plans, priorities, and programs with industry organizations including, but not limited to, the Pharmaceutical Research and Manufacturers of America (PhRMA), the Biotechnology Industry Organization (BIO), and the National Venture Capital Association (NVCA); (5) regular presentations to and panel discussions with industry representatives at public conferences; (6) demonstration of non-redundancy with industry projects as a selection criterion for relevant NCATS projects; (7) promotion of partnerships through the publication of notices in the **Federal** Register seeking partners in Collaborative Research and Development Agreements (CRADAs) to facilitate the development and commercialization of technologies; (8) publication of Requests for Information on NCATS plans, priorities, and programs in the Federal Register and NIH Guide; (9) sponsorship of regular workshops to identify priorities and solutions of topics related to translational science; and (10) periodic release of the NCATS e-newsletter, distribution of emails to NCATS stakeholder listservs, and announcements on NCATS Facebook page and through the NCATS Twitter account. In addition, the community will be able to inquire and comment on NCATS activities at any time by sending an email to info@ncats.nih.gov.

FOR FURTHER INFORMATION CONTACT: For further details please contact Stephen Seidel, Acting Director, Office of Policy, National Center for Advancing Translational Sciences, NIH, 6701 Democracy Blvd., Suite 900, Bethesda, MD 20892–4874; 301–435–0866; Email: seidels@mail.nih.gov.

Dated: May 8, 2013.

## Christopher P. Austin,

Director, National Center for Advancing Translational Sciences, National Institutes of Health.

[FR Doc. 2013–11526 Filed 5–14–13; 8:45 am]

BILLING CODE 4140-01-P